How are energy investors positioned?
Investing.com -- Ginkgo Bioworks Holdings (NYSE:DNA) stock rose 2.6% after the cell programming and biosecurity platform company announced a $4.66 million contract to deliver an automated anaerobic phenotyping platform to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL).
Under the agreement, Ginkgo will construct and install a fully integrated workcell comprising 18 different devices housed within a modular anaerobic chamber at EMSL’s Richland, Washington campus. The system will utilize Ginkgo Automation’s Reconfigurable Automation Cart technology, designed to enhance laboratory throughput, efficiency, and data quality.
The platform aims to enable EMSL scientists to remotely operate complex end-to-end anaerobic phenotyping workflows, potentially streamlining research processes in support of U.S. energy production and bioeconomy initiatives. Ginkgo’s technology includes a web-based software stack designed for programmatic control via API gateway access, which could enable AI-driven autonomous science capabilities.
"We are excited to support EMSL’s ambitious research goals with our automation technology," said Will Serber, General Manager of Ginkgo Automation. "Our automated systems are designed to empower partners like EMSL to realize the benefits of automation for research and development while maintaining control over their scientific workflows."
The company indicated that similar automation systems have been deployed across Ginkgo labs and at external customer sites, delivering increased throughput and data capture while decreasing cycle times and costs. The new platform is expected to be fully operational at EMSL later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.